These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38612820)

  • 21. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease.
    Jiang M; Wu N; Chen X; Wang W; Chu Y; Liu H; Li W; Chen D; Li X; Xu B
    J Int Med Res; 2019 Apr; 47(4):1453-1466. PubMed ID: 30871397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventive and therapeutic effects of natural products and herbal extracts on nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Cao Y; Fang X; Sun M; Zhang Y; Shan M; Lan X; Zhu D; Luo H
    Phytother Res; 2023 Sep; 37(9):3867-3897. PubMed ID: 37449926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic Liver Disease in Children and Adolescents.
    Smith SK; Perito ER
    Clin Liver Dis; 2018 Nov; 22(4):723-733. PubMed ID: 30266159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis.
    Esteban JPG; Asgharpour A
    Gastroenterol Clin North Am; 2020 Mar; 49(1):105-121. PubMed ID: 32033758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Sumida Y; Nakajima A; Itoh Y
    World J Gastroenterol; 2014 Jan; 20(2):475-85. PubMed ID: 24574716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
    Sfikas G; Psallas M; Koumaras C; Imprialos K; Perdikakis E; Doumas M; Giouleme O; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2021; 19(5):572-581. PubMed ID: 33059580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Saigo Y; Uno K; Ishigure T; Odake T; Ohta T
    In Vivo; 2024; 38(3):990-999. PubMed ID: 38688597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH.
    Sobhia ME; Kumari S; Kumar H; Gandhe A; Kaushik D; Kumar H; Jain J; Ankita ; Mallick M; Pavani B; Moudgil M; Patel D
    Curr Top Med Chem; 2023; 23(21):2027-2047. PubMed ID: 37455455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Options and Future Directions for NAFLD and NASH Treatment.
    Zhang C; Yang M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology.
    Noureddin M; Abdelmalek MF
    Clin Liver Dis; 2023 May; 27(2):397-412. PubMed ID: 37024215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA Methylation in Nonalcoholic Fatty Liver Disease.
    Hyun J; Jung Y
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice.
    Rajak S; Tewari A; Raza S; Gupta P; Chakravarti B; Anjum B; Tripathi M; Singh BK; Yen PM; Goel A; Ghosh S; Sinha RA
    Biochim Biophys Acta Mol Basis Dis; 2023 Apr; 1869(4):166662. PubMed ID: 36754244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on the therapeutic role of RNAi in NAFLD/NASH.
    Dehghan H; Ghasempour A; Sabeti Akbar-Abad M; Khademi Z; Sedighi M; Jamialahmadi T; Sahebkar A
    Prog Mol Biol Transl Sci; 2024; 204():45-67. PubMed ID: 38458743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.